Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.  Wipper B, Cooke MP, Winkelman JW.  Nat Sci Sleep. 2023 Oct 21;15:851-859. doi: 10.2147/NSS.S427403. PMID…

An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results,  K Aaron Geno, Adina Badea, Kara L Lynch, Paul Jannetto, Jacqueline A Hubbard, Robert D Nerenz, Mark A Cervinski,  The Jou…

Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.  Mariani, JJ, Dobbins, RL, Heath, A, Gray, F, Hassman, H.  Am J Addict. 2023; 1…

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.  Wipper B, Cooke MP, Winkelman JW.  Nat Sci Sleep. 2023 Oct 21;15:851-859. doi: 10.2147/NSS.S427403. PMID: 37…

An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine.  Pande LJ, Arnet RE, Piper BJ.  Pharmaceuticals (Basel). 2023 Oct 2;16(10):1397. doi: 10.3390/ph16101397. PMID: 37895868; PMCID…

Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.  Parkin S, Neale J, Strang J.  Int J Drug Policy. 2023 Oct 19;122:1042…